🇺🇸 FDA
Patent

US 10577344

Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins

granted A61PA61P35/00

Quick answer

US patent 10577344 (Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins) held by The Board of Regents of the University of Texas System expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61P, A61P35/00